Tildrakizumab (Ilumetri®) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/07/2019|
|Rapid review completed||28/08/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tildrakizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|